|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009566,
umls-concept:C0019080,
umls-concept:C0019134,
umls-concept:C0021107,
umls-concept:C0030163,
umls-concept:C0035647,
umls-concept:C0087111,
umls-concept:C0162589,
umls-concept:C0442805,
umls-concept:C0699733,
umls-concept:C1554184
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2010-5-21
|
|
pubmed:abstractText |
This study was designed to assess the risk of significant bleeding complications in patients receiving antiplatelet or anticoagulation medications at the time of implantable cardioverter-defibrillator (ICD) device implantation.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1558-3597
|
|
pubmed:author |
pubmed-author:BergerRonald DRD,
pubmed-author:BrinkerJeffrey AJA,
pubmed-author:CalkinsHughH,
pubmed-author:ChengAlanA,
pubmed-author:DalalDarshanD,
pubmed-author:HalperinHenryH,
pubmed-author:HenriksonCharles ACA,
pubmed-author:LengCharles TCT,
pubmed-author:MarineJoseph EJE,
pubmed-author:NazarianSamanS,
pubmed-author:SinhaSunilS,
pubmed-author:SpraggDavid DDD,
pubmed-author:TomaselliGordon FGF,
pubmed-author:TompkinsChristineC
|
|
pubmed:copyrightInfo |
Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
25
|
|
pubmed:volume |
55
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2376-82
|
|
pubmed:dateRevised |
2010-8-2
|
|
pubmed:meshHeading |
pubmed-meshheading:20488310-Aged,
pubmed-meshheading:20488310-Aged, 80 and over,
pubmed-meshheading:20488310-Aspirin,
pubmed-meshheading:20488310-Case-Control Studies,
pubmed-meshheading:20488310-Confidence Intervals,
pubmed-meshheading:20488310-Defibrillators, Implantable,
pubmed-meshheading:20488310-Drug Therapy, Combination,
pubmed-meshheading:20488310-Female,
pubmed-meshheading:20488310-Follow-Up Studies,
pubmed-meshheading:20488310-Heparin,
pubmed-meshheading:20488310-Humans,
pubmed-meshheading:20488310-Length of Stay,
pubmed-meshheading:20488310-Male,
pubmed-meshheading:20488310-Middle Aged,
pubmed-meshheading:20488310-Odds Ratio,
pubmed-meshheading:20488310-Pacemaker, Artificial,
pubmed-meshheading:20488310-Platelet Aggregation Inhibitors,
pubmed-meshheading:20488310-Postoperative Care,
pubmed-meshheading:20488310-Postoperative Hemorrhage,
pubmed-meshheading:20488310-Prevalence,
pubmed-meshheading:20488310-Reference Values,
pubmed-meshheading:20488310-Retrospective Studies,
pubmed-meshheading:20488310-Risk Assessment,
pubmed-meshheading:20488310-Ticlopidine,
pubmed-meshheading:20488310-Warfarin
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation.
|
|
pubmed:affiliation |
Johns Hopkins Hospital, Baltimore, Maryland, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
